Abstract:e20041 Background: Few studies focused on the risk-adapted therapy for advanced-stage natural killer/T-cell lymphoma (NKTCL) due to poor prognosis. Methods: Data of 406 patients with advanced-stage NKTCL from 20 Chinese institutions between 2000 and 2015 were retrospectively analyzed. To develop a prognosis index model for advanced-stage NKTCL, all patients were divided into the primary cohort from South China (n = 198) and the validation cohort from North China (n = 208). Clinical factors related to survival in the primary cohort were identified to construct a new prognosis index model. An external validation for the prognosis index model was performed in the validation cohort. Stratified by the prognosis index model, survival benefit for treatment models was assessed. Results: The median age was 42 years with the ratio of male/female of 2.5:1. Extra-nodal involvement was observed in 72.4% of patients. More than one third of patients received asparaginase (Asp)–containing chemotherapy. In addition, radiotherapy was administrated in 135 (33.3%) patients. The overall response rate (ORR) and complete remission (CR) rate were 59.3% and 38.3% in 337 available patients. The expected 3-year progression-free survival (PFS) and overall survival (OS) rates were 26.9% and 37.3%, respectively. Based on 3 clinical variables including ECOG-PS > 1, elevated LDH and solid organs involvement, a new prognosis index model (ASPRIN) was developed and showed superior discrimination than current models including IPI, KPI and PINK in this particular population. The expected 3-year OS rates in the primary and validation cohort were 54.8% and 52.9% in the low risk group (with 0-1 risk factor), 34.4% and 38.0% in the intermediate risk group (with 2 risk factors), 13.8% and 10.6% in the high risk group (with 3-4 risk factors), respectively. Stratified by ASPRIN model, combined radio-chemotherapy provided better survival benefit than chemotherapy alone regardless of chemotherapy regimens in the low risk group (3-year PFS 52.6% vs. 22.6%, P < 0.001; 3-year OS 72.8% vs. 35.8%, P < 0.001), while Asp–containing chemotherapy improved survival with an increase of about 10%-15% in PFS and OS compared with non–Asp–containing chemotherapy in the intermediate and high risk groups. Conclusions: The outcome of advanced-stage NKTCL is still poor and heterogeneous even in the era of Asp–containing chemotherapy, which highlighted the need of establishing more effective risk-adapted therapeutic strategies.

Effect of Age As a Continuous Variable on Survival Outcomes and Treatment Selection in Patients with Extranodal Nasal-Type NK/T-cell Lymphoma from the China Lymphoma Collaborative Group (CLCG).

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000-2015)

Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma

Unfavorable Prognosis of Elderly Patients with Early-Stage Extranodal Nasal-Type NK/T-cell Lymphoma

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non -small cell lung cancer receiving chemoradiotherapy

Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer

Demographics, Risk Factors and Survival Analysis of Lung Cancer in Young Adults (&lt;30 Years) in China-A Retrospective Cohort Study

Effect of Age As a Continuous Variable in Early-Stage Endometrial Carcinoma: a Multi-Institutional Analysis in China

Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiation Therapy for Patients with Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/− systemic therapy in locally advanced head and neck cancer

Risk-adapted Therapy for Advanced-Stage Natural Killer/t-Cell Lymphoma: an Analysis from the China Lymphoma Collaborative Group Study.

Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group

Analysis of Survival Data in Patients with Advanced Non-Small-Cell Lung Cancer Aged 60 Years and Over

[A Retrospective Analysis: Comparison of the Clinical Characteristics and Prognosis in Elderly and Young Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.].

Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I–II follicular lymphoma from the SEER database (2000–2015)

Progression-free Survival at 24 Months and Subsequent Survival of Patients with Extranodal NK/T-cell Lymphoma: a China Lymphoma Collaborative Group (CLCG) Study.

Prognostic Factors in Older Patients with Advanced Non-Small Cell Lung Cancer in China.

Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].